<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3990330</article-id><article-id pub-id-type="publisher-id">2051-1426-1-S1-P132</article-id><article-id pub-id-type="doi">10.1186/2051-1426-1-S1-P132</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Krug</surname><given-names>Lee</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>di Pietro</surname><given-names>Alessandra</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Narwal</surname><given-names>Rajesh</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Robbins</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Fu</surname><given-names>Dongyue</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Shalabi</surname><given-names>Aiman</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Ibrahim</surname><given-names>Ramy</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Calabro</surname><given-names>Luana</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Kindler</surname><given-names>Hedy</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib></contrib-group><aff id="I1"><label>1</label>Memorial Sloan-Kettering Cancer Center, New York City, NY, USA</aff><aff id="I2"><label>2</label>MedImmune, LLC, Gaithersburg, MD, USA</aff><aff id="I3"><label>3</label>University Hospital of Siena, Siena, Italy</aff><aff id="I4"><label>4</label>The University of Chicago, Chicago, IL, USA</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>7</day><month>11</month><year>2013</year></pub-date><volume>1</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Abstracts of the 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)</named-content><named-content content-type="supplement-editor">Carl Ruby</named-content><named-content content-type="supplement-sponsor">This supplement has not been sponsored. The Supplement Editor declares that he has no competing interests.</named-content></supplement><fpage>P132</fpage><lpage>P132</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Krug et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Krug et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/1/S1/P132"/><conference><conf-date>8-10 November 2013</conf-date><conf-name>Society for Immunotherapy of Cancer 28th Annual Meeting</conf-name><conf-loc>National Harbor, MD, USA</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Malignant mesothelioma (MM) is an uncommon cancer, caused principally by asbestos exposure. No treatments after first-line platinum-pemetrexed [<xref ref-type="bibr" rid="B1">1</xref>] have shown survival benefit [<xref ref-type="bibr" rid="B2">2</xref>], thus novel approaches are needed. Asbestos exposure induces immunosuppression and immune dysfunction in the mesothelium environment, mainly by hyperactivation of regulatory T lymphocytes and over-production of cytokines that inhibit cytotoxic T lymphocytes and natural killer cells [<xref ref-type="bibr" rid="B3">3</xref>]. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, CD152) modulates and eventually switches off T cell activation. Tremelimumab (treme) binds to the CTLA-4 antigen, preventing its negative regulatory signal to cytotoxic T cells. Results from a single arm phase 2 study of treme in 29 patients with MM who progressed on a platinum-based regimen showed promising 1- and 2- year survival rates and a safety profile consistent with previous treme studies [<xref ref-type="bibr" rid="B4">4</xref>]. This study has been expanded to enroll 29 patients currently treated with an optimized dosing schedule.</p></sec><sec><title>Study design</title><p>This is a phase 2, randomized, double-blind, placebo-controlled study. Patients with unresectable pleural or peritoneal MM who progressed following 1or 2 prior treatments, including a first-line platinum-pemetrexed regimen, will be randomized in a 2:1 ratio to receive either treme or placebo. Randomization will be stratified by EORTC status (low- vs high-risk), line of therapy (second vs third), and anatomical site (pleural vs peritoneal). Enrollment will include 180 subjects at approximately 150 centers in multiple countries. Recruiting began in May 2013.</p></sec><sec><title>Endpoints</title><p>Primary: overall survival. Secondary: durable disease-control rate (DCR); progression-free survival (PFS); patient-reported outcomes (pain, disease-related symptoms, and time to deterioration of disease-related symptoms); duration of response and overall response rate (ORR); treme safety profile, immunogenicity, and pharmacokinetics. Exploratory: DCR, PFS, duration of response and ORR based on immune related response criteria, health-related quality of life, disease-related symptoms, pain, and health status in patients with durable clinical activity. The association of biomarkers with treme and clinical outcomes will also be explored.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="other"><name><surname>Vogelzang</surname><given-names>NJ</given-names></name><etal/><source>J Clin Onc</source><year>2003</year><volume>1</volume><fpage>2636</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.11.136</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="other"><name><surname>Ceresoli</surname><given-names>GL</given-names></name><etal/><source>Cancer Treat Rev</source><year>2010</year><volume>1</volume><fpage>24</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2009.09.003</pub-id><pub-id pub-id-type="pmid">19879055</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="other"><name><surname>Maeda</surname><given-names>M</given-names></name><etal/><source>J Immunotoxicol</source><year>2010</year><volume>1</volume><fpage>268</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.3109/1547691X.2010.512579</pub-id><pub-id pub-id-type="pmid">20849352</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="other"><name><surname>Calabr&#x000f2;</surname><given-names>L</given-names></name><etal/><source>Lancet Oncol</source><year>2013</year><volume>1</volume><fpage>1104</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70381-4</pub-id><pub-id pub-id-type="pmid">24035405</pub-id></mixed-citation></ref></ref-list></back></article>